Dr. Dandamudi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9320 State Road 54
Trinity, FL 34655Phone+1 727-493-2513Fax+1 877-917-2336
Education & Training
- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2009 - 2012
- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Clinical Pharmacology, 2007 - 2009
- Westchester Medical CenterResidency, Internal Medicine, 1998 - 2000
- Edgewater HospitalResidency, Internal Medicine, 1997 - 1998
- Edgewater HospitalInternship, Internal Medicine, 1997 - 1998
- Gandhi Medical CollegeClass of 1994
Certifications & Licensure
- NH State Medical License 2007 - Present
- FL State Medical License 2012 - 2026
- NY State Medical License 2001 - 2008
- IL State Medical License 1997 - 2000
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Publications & Presentations
PubMed
- 30 citationsThe effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.Geoffrey I. Shapiro, Richard G. Frank, Uday B. Dandamudi, Thomas Hengelage, Lily Zhao
Cancer Chemotherapy and Pharmacology. 2012-02-01 - 23 citationsA phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.Uday B. Dandamudi, Musie Ghebremichael, Jeffrey A. Sosman, Joseph I. Clark, David F. McDermott
Journal of Immunotherapy. 2013-11-01 - 4 citationsLack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancerUday B. Dandamudi, Laurel M. Adams, Brendan M. Johnson, John W. Bauman, Shannon R. Morris
Cancer Chemotherapy and Pharmacology. 2011-04-01
Abstracts/Posters
- A Phase-I dose escaIatìon study of cycIIcaI Weekly Temozolomide (TMZ) combined with weekly PegyIated Interferon AIfa-Zb (PEG-IFN) in patients (pts) with refractory and...Dandamudi UB. BeeIan AP, Reddy NJ, Crosby NC, Ernstoff IVIS & Lewis LD, CIin Pharm & Ther
- Comparative study of CYPZCQ and VKORC1 (-1639G>A) genotyping with the Nanopshere Verigene System and the Third VVave Gtechnologies invaderAssay.Dandamudi UB, Lefferts JA, Schwab MC, Bean JR, Lee HK, Tsongalis GJ, Lewis LD, The lXth World Conference on Clinical
- Effect of oral (PO) casopitant, a novel NK~1 receptor antagonist, on the pharmacokinetics (PK) and safety profile of intravenous (IV) docetaxel.Adams L, Johnson B, Bauman J, Lebowitz P, Zhang, K. Webb, T. Gartner, E. Hohl R, Dandamudi UB. & Lewis, L, EJC Supplements Iss
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: